FDA 21 CFR Part 11 Electronic Records - Electronic Signatures

The "FDA 21 CFR Part 11 Electronic Records - Electronic Signatures" standard, published by the U.S. Food and Drug Administration (FDA) under the Code of Federal Regulations (CFR), describes the criteria by which the agency evaluates electronic records, electronic signatures, and handwritten signatures on electronic records as reliable, trustworthy, and generally equivalent to paper records and handwritten signatures on paper.

This section applies to records in electronic form created, modified, maintained, archived, received, or transmitted under any record requirements specified in agency regulations. This section also applies to electronic records submitted to the agency under the requirements of the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, even if such records are not specifically identified in agency regulations. However, this section does not apply to paper records that are or have been transmitted by electronic means.

If electronic signatures and their associated electronic records meet the requirements of this section, agency electronic signatures are considered equivalent to full handwritten signatures, initials, and other generic signatures required by agency regulations, unless specifically exempted by applicable legal regulations.

Computer systems (including hardware and software), controls, and associated documentation maintained under this section must be available for and subject to FDA inspection.

Situations where this standard does not apply are detailed in the standard.

FDA 21 CFR Part 11 is vital to companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries that use computerized systems for regulatory compliance.

The objectives of this standard can be listed as follows:

• Ensuring the integrity, authenticity and confidentiality of electronic records.
• Ensuring the secure use of electronic signatures instead of traditional handwritten signatures.
• Establishing a consistent and reliable system for storing, retrieving and auditing digital records.

By complying with this regulation, companies can leverage digital technology while maintaining compliance with FDA requirements.

The FDA 21 CFR Part 11 standard applies to:

• Electronic records created, modified, maintained, archived, received, or transmitted under any records requirements established by FDA regulations.
• Electronic signatures are used in place of handwritten signatures on paper documents required by FDA regulations.

It covers all electronic systems used in FDA-regulated environments, including laboratory systems, manufacturing systems, clinical trial management systems, and document management platforms.

The key requirements of the FDA 21 CFR Part 11 standard are:

• Validation of systems: Systems that manage electronic records should be validated to ensure accuracy, reliability, consistent intended performance, and the ability to distinguish invalid or altered records.
• Audit trails: Systems must have secure, computer-generated audit trails that record the date and time of entries and changes, who made them, and the reason for the changes.
• Access control and security: Only authorized individuals should have access to the system. Strong security measures (such as unique usernames and passwords, biometric controls) are required.
• Electronic signatures: Electronic signatures must be unique to an individual and must not be reused or reassigned. The signature must include the name, date and time of the signature, and the purpose (e.g., approval, review).
• Records storage and retrieval: Records must be retained for the required time period and be readily available for inspection by the FDA.
• Training: Staff should be trained to perform assigned tasks and understand their responsibilities regarding electronic records and signatures.

The benefits of compatibility can be listed as follows:

• Improved efficiency and speed in data processing
• Enhanced data integrity and reduced risk of error or fraud
• Regulatory acceptance of digital records and processes
• Streamlined audits and inspections with full electronic traceability

Challenges in implementing this standard include:

• Implementing compliant systems can be costly and complex
• Validation efforts require significant planning, documentation, and testing.
• Maintaining ongoing compliance includes regular monitoring, training and audits.

Ultimately, the FDA 21 CFR Part 11 standard is a critical regulation for organizations that rely on electronic records and signatures. Properly understanding and implementing its requirements helps ensure data integrity, streamline regulatory compliance, and improve overall operational efficiency. By adopting a risk-based approach and leveraging validated systems, companies can align with FDA expectations while embracing the benefits of digital transformation.

FDA 21 CFR Part 11 is essential because it provides a legal and regulatory framework to ensure the integrity, authenticity, and security of electronic records and electronic signatures in FDA-regulated environments. Key reasons why this regulation is important include:

• Ensures data integrity and reliability: Electronic records must be as reliable and tamper-resistant as paper records. This standard establishes controls such as audit trails and system validation to prevent:
  • Unauthorized access or modifications
  • Data manipulation
  • Loss of traceability

This helps ensure that decisions made using electronic records (e.g., drug approvals, safety assessments) are based on accurate and unaltered data.

• Supports the use of electronic signatures: Electronic signatures streamline workflows by replacing handwritten signatures. This standard provides:
  • Electronic signatures are unique to each user
  • Legally equivalent to handwritten signatures
  • It is secure and verifiable

This is crucial for regulatory acceptance of digital processes.

• Allows FDA to conduct inspections efficiently: This standard requires electronic records to be easily retrievable and traceable. This makes it easier for FDA inspectors to:
  • Verifying compliance during audits
  • Reviewing records in a consistent and structured manner
  • It also facilitates remote audits and faster regulatory reviews.
• Drives digital transformation in regulated industries: By establishing clear guidelines for electronic systems, this standard encourages life sciences companies to adopt modern digital technologies (e.g., cloud systems) while remaining compliant. This helps:
  • Increasing efficiency
  • Reducing manual errors
  • Reducing operational costs
• Reduces the risk of fraud and abuse: Without appropriate controls, electronic systems can be misused to falsify records or conceal data. This standard includes measures such as:
  • Unique user ID
  • Password checks
  • Audit trails

These safeguards protect public health by ensuring that companies cannot manipulate data regarding product safety, effectiveness, or quality.

• Maintains public and regulatory trust: Compliance with this standard demonstrates that a company takes data management seriously. This builds trust by:
  • Regulatory bodies
  • Partners and sponsors
  • Public and healthcare providers

The FDA 21 CFR Part 11 standard is necessary because it bridges the gap between traditional paper records and modern electronic systems and ensures that electronic data used in regulated activities is reliable, secure, and legally valid.

Our organization, which has been supporting businesses across all sectors for years with a wide range of testing, measurement, analysis, and evaluation activities, has a strong team of employees who closely follow global developments in science and technology and are constantly improving themselves. In this context, we also provide testing services that comply with the FDA 21 CFR Part 11 Electronic Records - Electronic Signatures standard.